Controlling when and where an immune-prompting molecule is active may make treatment safer, more effective.
Many women report symptoms early on, which are often dismissed by providers, according to one UW Medicine oncology expert.
The study provides insights into how the cancers resist treatments, and which patients may benefit from treatment.
A laboratory breakthrough in cell targeting may improve the safety of cancer-killing CAR T cells.
